Estrella Immunopharma, Inc. (ESLAW)
- Previous Close
0.0920 - Open
0.0920 - Bid --
- Ask --
- Day's Range
0.0920 - 0.0920 - 52 Week Range
0.0920 - 0.0920 - Volume
1,990 - Avg. Volume
-- - Market Cap (intraday)
-- - Beta (5Y Monthly) -0.09
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.
www.estrellabio.comRecent News: ESLAW
View MoreCompare To: ESLAW
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ESLAW
View MoreValuation Measures
Market Cap
--
Enterprise Value
--
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-174.75%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-11.11M
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
2.48M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
2.81M